Halozyme Therapeutics (NASDAQ:HALO) Director Matthew Posard Sells 18,996 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew Posard sold 18,996 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director directly owned 58,839 shares of the company’s stock, valued at $6,339,313.86. The trade was a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Up 1.1%

HALO opened at $109.68 on Friday. The business’s fifty day moving average is $95.95 and its two-hundred day moving average is $78.09. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.45 billion, a price-to-earnings ratio of 32.74, a PEG ratio of 0.41 and a beta of 0.88. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 8.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Talon Private Wealth LLC purchased a new stake in shares of Halozyme Therapeutics during the second quarter worth about $839,000. Sequoia Financial Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $359,000. Tidal Investments LLC lifted its stake in shares of Halozyme Therapeutics by 13.5% during the second quarter. Tidal Investments LLC now owns 190,305 shares of the biopharmaceutical company’s stock valued at $14,895,000 after buying an additional 22,707 shares during the period. WINTON GROUP Ltd lifted its stake in shares of Halozyme Therapeutics by 704.6% during the second quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after buying an additional 52,848 shares during the period. Finally, Engineers Gate Manager LP boosted its position in Halozyme Therapeutics by 6.7% during the second quarter. Engineers Gate Manager LP now owns 46,172 shares of the biopharmaceutical company’s stock worth $3,614,000 after acquiring an additional 2,889 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on HALO shares. HC Wainwright restated a “buy” rating and set a $115.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Citizens Jmp raised their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. TD Cowen lifted their price objective on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Wells Fargo & Company upped their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Recent investor commentary highlighted Halozyme’s attractive growth profile, supported by its drug-delivery technology platform, recurring royalty revenue and strong earnings outlook. The company’s latest reported quarter also exceeded expectations, with revenue rising 47.7% year over year and EPS surpassing consensus estimates. Three Reasons Why Growth Investors Shouldn’t Overlook Halozyme
• Neutral Sentiment: Halozyme’s presentation at the H.C. Wainwright investment conference kept attention focused on its growth strategy and pipeline, although no clearly market-moving new guidance was reported. Halozyme H.C. Wainwright Conference Presentation
• Negative Sentiment: Halozyme announced a proposed private offering of $1.05 billion of convertible senior notes due 2033. The financing could provide substantial capital on potentially favorable terms, but it also increases leverage and may dilute existing shareholders if the notes are converted, creating an overhang for the stock. Final terms remain subject to market conditions. Halozyme Announces Proposed Convertible Notes Offering
• Negative Sentiment: Director Matthew Posard sold 18,996 shares worth approximately $2.05 million, reducing his position by 24.4%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal, but insider selling can still weigh modestly on sentiment. Halozyme Director Stock Sale SEC Filing

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.